The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 996.80
Bid: 999.80
Ask: 1,000.50
Change: 11.20 (1.14%)
Spread: 0.70 (0.07%)
Open: 985.00
High: 1,006.00
Low: 984.20
Prev. Close: 985.60
SN. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of robotics-assisted knee replacement

13 Nov 2017 13:00

RNS Number : 3102W
Smith & Nephew Plc
13 November 2017
 

 

Smith & Nephew's NAVIO™ Surgical System launches the first robotics-assisted bi-cruciate retaining total knee replacement

13 November 2017

 

Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announces completion of the world's first robotics-assisted bi-cruciate retaining total knee replacement procedures.

 

The NAVIO robotics-assisted surgical system aids in implanting the JOURNEY™ II XR (bi-cruciate retaining total knee system) which is one of the only total knee designs allowing retention of the ACL, and is designed to improve patient satisfaction. 1

 

With this launch, NAVIO now offers both partial and total knee options that include the first and only robotics-assisted bi-cruciate retaining knee procedure, commercially available today.

 

Drs. Vivek Neginhal (WV), David Rovinsky(HI), and David Fabi (CA) recently performed the first cases. "I believe that the NAVIO is able to provide critical elements of success for the JOURNEY II XR, such as accuracy of tibia component placement and a streamlined surgical technique." Dr. Neginhal further commented: "I was amazed at how fluid the knee motion was on the first postop day. My patients have expressed great satisfaction so far. I believe that NAVIO's accuracy and flexibility of use combined with JOURNEY II XR's retention of the patient's cruciate ligaments and physiological design will truly increase patients' function and satisfaction."

 

The NAVIO is a next generation handheld robotics platform designed to aid surgeons with implant alignment, ligament balancing and bone preparation - key factors that can drive implant survivorship.2,3 The small footprint of NAVIO allows for set up and portability. Furthermore, the NAVIO robotics-assisted system does not require a preoperative image, such as a CT scan. This allows patients to receive the benefits of robotics-assistance without the extra steps, costs, and radiation associated with additional preoperative imaging.4

 

"The JOURNEY II XR bi-cruciate retaining knee has the potential to deliver the best possible outcome for the surgeon and patient through the preservation of important anatomical structures such as the ACL. The NAVIO robotics-assisted surgical system enables accurate tibial implant placement to deliver a more reproducible surgical technique. We are proud to be the only company to offer the unique combination of NAVIO robotics-assistance and the JOURNEY II XR Knee System," said Mike Donoghue, Senior Vice President of Global Marketing, Orthopaedics at Smith & Nephew.

 

References

1. Moro-Oka, Taka-Aki, Marc Muenchinger, Jean Pierre Canciani, and Scott A. Banks."Comparing in VivoKinematics of Anterior Cruciate-retaining and Posterior Cruciate-retaining Total Knee Arthroplasty." KneeSurgery, Sports Traumatology, Arthroscopy 15.1 (200&): 93:99. Web.

2. Sharkey, P., et al. "Why Are Total Knee Arthroplasties Failing Today?" Clinical Orthopaedics and Related Research. 2002 Nov;404:7-13.

3. Siddique, N., Ahmad, Z. "Revision of Unicondylar to Total Knee Arthroplasty: A Systematic Review" The Open Orthopaedics Journal 2012;6; (Suppl 2: M2) 268-275

4. Sg2 Healthcare Intelligence. Technology Guide: Orthopedic Surgical Robotics. 2014.25. Readmissions Reduction Program (HRRP). CMS.gov. Page last Modified: 04/18/2016 5:08 PM.

- ends -

Enquiries

Media

Charles Reynolds

+44 (0) 1923 477314

Smith & Nephew

Dave Snyder

+1 (978) 749-1440

Smith & Nephew

Simon Conway / Debbie Scott

+44 (0) 20 3727 1000

FTI Consulting

 

Investors

Ingeborg Øie

+44 (0) 20 7960 2285

Smith & Nephew

About Smith & NephewSmith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Forward-looking StatementsThis document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKNDDKBDDODD
Date   Source Headline
1st May 20244:47 pmRNSResult of AGM
1st May 20241:35 pmRNSTotal Voting Rights
1st May 20247:00 amRNSQ1 2024 Trading Update
23rd Apr 20249:46 amRNSTiming of Smith+Nephew Q1 2024 Trading Report
2nd Apr 20241:43 pmRNSTotal Voting Rights
2nd Apr 20241:19 pmRNSDirector/PDMR Shareholding
28th Mar 20247:00 amRNSDirectorate Change
14th Mar 20247:00 amRNSSMITH+NEPHEW PRICES USD BOND ISSUE
13th Mar 20244:03 pmRNSDirector/PDMR Shareholding
11th Mar 20246:20 pmRNSDirector/PDMR Shareholding
11th Mar 20242:41 pmRNSAnnual Financial Report
1st Mar 202411:26 amRNSTotal Voting Rights
27th Feb 20247:00 amRNSFinal Results
23rd Feb 20247:00 amRNSChange in Director Details
14th Feb 20241:47 pmRNSBlock listing Interim Review
1st Feb 20242:12 pmRNSTotal Voting Rights
30th Jan 20247:00 amRNSNotice of Results
17th Jan 20243:05 pmRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSAcquisition
4th Jan 202410:02 amRNSDirectorate Change
2nd Jan 202411:32 amRNSTotal Voting Rights
22nd Dec 202310:36 amRNSDirector/PDMR Shareholding
6th Dec 20237:00 amRNSDirectorate Change
1st Dec 202311:27 amRNSTotal Voting Rights
29th Nov 20237:00 amRNSMeet the Management Event
22nd Nov 20237:00 amRNSAcquisition
14th Nov 20233:25 pmRNSDirector/PDMR Shareholding
10th Nov 20233:30 pmRNSDirector/PDMR Shareholding
10th Nov 202312:56 pmRNSDirector/PDMR Shareholding
9th Nov 20235:03 pmRNSDirector/PDMR Shareholding
3rd Nov 20232:30 pmRNSDirector/PDMR Shareholding
2nd Nov 20237:01 amRNSAppointment of John Rogers as CFO
2nd Nov 20237:00 amRNS3rd Quarter 2023 Trading Report
1st Nov 20234:36 pmRNSTotal Voting Rights
1st Nov 202310:09 amRNSMEET THE MANAGEMENT EVENT
20th Oct 202310:34 amRNSSTERLING AMOUNT OF DIVIDEND
13th Oct 20238:58 amRNSNotice of Results
2nd Oct 20234:29 pmRNSTotal Voting Rights
14th Sep 20237:00 amRNSBoard Changes
1st Sep 20233:47 pmRNSTotal Voting Rights
23rd Aug 20233:41 pmRNSDirector/PDMR Shareholding
15th Aug 202311:59 amRNSDirector/PDMR Shareholding
14th Aug 20232:27 pmRNSDirector/PDMR Shareholding
7th Aug 202310:51 amRNSBlock listing Interim Review
3rd Aug 20237:02 amRNSDirectorate Change
3rd Aug 20237:00 amRNSHalf-year Report
1st Aug 202312:37 pmRNSTotal Voting Rights
21st Jul 20231:45 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSNotice of Results
3rd Jul 20234:07 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.